Effects of Glucagon Like Peptide-1 on No-reflow

Sponsor
Chen Wei Ren, MD
Study ID
NCT02507128
Status
Unknown

Conditions

  • Acute ST-segment Elevation Myocardial Infarction

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Liraglutide were taken 30 min before PCI.
  • placebo — DRUG
    Placebo were taken 30 min before PCI.

Study Details

The investigators planned to evaluate the effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction (STEMI).

Key Dates

Start date
Jul 31, 2015
Status verified
Jul 2015
Primary completion
Jul 31, 2016
Completion
Jul 31, 2016

Study Design

Enrollment
190 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: GLP-1 group
    The treatment started 30 min before PCI with a dose of 1.8 mg liraglutide (the treatment was administered in the ambulance).
  • Placebo Comparator: Control group
    the treatment started 30 min before PCI with a dose of 1.8 mg placebo (the treatment was administered in the ambulance).

Primary Outcome Measure

a change in the prevalence of no-reflow [ Time Frame: immediately after PCI ]

Central Contacts